Skip to content
2000
Volume 16, Issue 1
  • ISSN: 1570-1611
  • E-ISSN: 1875-6212

Abstract

Background: Hypertension (HT), albeit a modifiable risk factor of cardiovascular morbidity and mortality, remains one of the main contributors to the total disease burden internationally and, thus, inevitably one of the basic cost drivers in healthcare systems. Conclusion: Taking the above into account, this brief narrative review aims at presenting the main findings of the international health economics literature on HT with regards to four key areas: a) the costs attributable to HT, b) the effects of HT on patient well-being, c) the cost-effectiveness of pharmaceutical interventions against high blood pressure, and, d) the costs and benefits of preventive measures against HT. Bearing in mind the available evidence on disease costs and the efficiency of interventions, HT must constitute a primary objective of modern health policy, internationally.

Loading

Article metrics loading...

/content/journals/cvp/10.2174/1570161115666170413145125
2018-01-01
2025-09-02
Loading full text...

Full text loading...

/content/journals/cvp/10.2174/1570161115666170413145125
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test